### Learner Notification

**MED Learning Group**

**The Emerging Standard of Care: Immunotherapy in Non-Melanoma Skin Cancer**

**June 5, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

Regeneron Pharmaceuticals, Inc.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Discuss cutaneous squamous cell carcinoma tumor cell dissemination and post-surgical recurrence.
2. Evaluate the application of immune checkpoint inhibition in the neo-adjuvant setting of cutaneous squamous cell carcinoma.
3. Review the efficacy and safety data of immunotherapy in patients with either advanced basal cell carcinoma or advanced cutaneous squamous cell carcinoma.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interst: Relationship** |
| Felecia | Beachum | NA |
| Naomi | De Brito | NA |
| Kim L. | Farina | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Nicole | Longo | NA |
| Aimee | Meissner | NA |
| David M. | Miller | Merck, EMD Serono, Regeneron, Sanofi Genzyme, Pfizer, Castle Biosciences, Checkpoint Therapeutics: Scientific/Medical Advisory Board, Checkpoint Therapeutics, Avstera Therapeutics: Stock Shareholder, Regeneron, Kartos Therapeutics. NeoImmune Tech, Inc, Project Data Sphere, ECOG-ACRIN, the American Skin Association: Research Funding |
| Vishal A. | Patel | He has received consulting fees from Regeneron, Sanofi, PhD Biosciences, Almirall, and Jounce Therapeutics. He is on the Speakers Bureau for Regeneron, Sanofi, and Almirall, and has ownership interests in Avstera Therapeutics, Lazarus AI, and Science 37. |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)